Evidence map›Paper›PMID 36245754›Full record

ArticleOphthalmology science2022

A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.

Alan Sugar, Munira Hussain, Winston Chamberlain, Reza Dana, David Patrick Kelly, Christopher Ta, John Irvine, Melissa Daluvoy, Victor Perez, Joshua Olson and 6 more

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Blood Derivatives in the Therapy of Ocular Surface Diseases.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

Alan SugarWK Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan.
Munira HussainWK Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan.
Winston ChamberlainCasey Eye Institute, and Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon.
Reza DanaDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.
David Patrick KellyEye Associates Northwest PC, Seattle, Washington.
Christopher TaDepartment of Ophthalmology, School of Medicine, Stanford University, Stanford, California.
John IrvineDoheny Eye Center, UCLA, Los Angeles, California.
Melissa DaluvoyDuke University Eye Center, Durham, North Carolina.
Victor PerezDuke University Eye Center, Durham, North Carolina.
Joshua OlsonDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.
Vishal JhanjiUPMC Eye Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Terence A WaltsCambium Medical Technologies LLC, Atlanta, Georgia.
Robert Doyle StultingCambium Medical Technologies LLC, Atlanta, Georgia.
Edmund K WallerCambium Medical Technologies LLC, Atlanta, Georgia.
Neera JagirdarCambium Medical Technologies LLC, Atlanta, Georgia.
Cambium Dry Eye Study Group
Doheny Eye Institute · USDuke University · USW.K. Kellogg Foundation · USUniversity of Minnesota · USEmory University · USMassachusetts Eye and Ear Infirmary · USNorthwest Eye Surgeons · USOregon Health & Science University · USStanford University · USUniversity of Pittsburgh Medical Center · USWoolfson Eye Institute · US

Funding

Immune Mechanisms in Ocular Graft versus Host DiseaseR01EY024484 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LEVY, ROBERT BENJAMIN, PEREZ, VICTOR L · 2014 to 2025
$5.1M
NEI NIH HHS R01 EY024484
6 · The paper itself

Abstract

Purpose: The purpose of the study was to evaluate, as a pilot trial, safety and tolerability of CAM-101 10% and 30% topical ophthalmic fibrinogen-depleted human platelet lysate (FD hPL) solution in patients with dry eye disease (DED) secondary to graft-versus-host disease (GvHD) after 6 weeks of treatment. Design: A phase I/II, pilot, prospective, multicenter, randomized, double-masked clinical trial. Participants: Patients with DED secondary to GvHD. Methods: Sixty-four adult patients were stratified by "symptom severity" (Ocular Surface Disease Index [OSDI], ocular discomfort Visual Analog Scale (VAS), ocular symptom frequency, and use of artificial tears) and then randomized 1:1:1 to CAM-101 (FD hPL) at 10% or 30% concentration or an electrolyte (Plasma-Lyte A) vehicle control, 1 drop in both eyes, 4 times daily, for 42 days. After 42 days, control patients were offered 42 days of open-label treatment with 30% FD hPL. Main Outcome Measures: Primary outcome safety measures were ocular and systemic adverse events and the number of patients in each group with clinically significant change from normal to abnormal in any ocular findings. Secondary outcomes were changes from baseline to day 42 in ocular discomfort, OSDI, fluorescein corneal staining, and lissamine green conjunctival staining relative to the vehicle control. The ocular symptom frequency was assessed on a 100-point VAS. Results: FD hPL 10% and 30% were safe and well tolerated. Relative to the vehicle control, significant decreases from baseline to day 42 were seen in the FD hPL 30% group with regard to ocular discomfort (mean decrease = -18.04; Conclusions: Fibrinogen-depleted human platelet lysate appears to be well tolerated, with no significant toxicity at concentrations of 10% and 30%. These initial data suggest some efficacy, especially for subjective outcome measures relative to baseline assessments and treatment with the vehicle, but larger studies are needed to confirm these effects.

Indexed as

AE, adverse eventASTs, autologous serum tearsCI, confidence intervalDED, dry eye diseaseDry eye diseaseFD hPL, fibrinogen-depleted human platelet lysateGraft versus host diseaseGvHD, graft-versus-host diseaseHSCT, hematopoietic stem cell transplantHuman plateletOcular surfaceOSDI, ocular surface disease indexPRP, platelet-rich plasmaSAE, severe adverse eventSerum tearsVAS, Visual Analog Scale

Identifiers

PMID36245754
PMCPMC9562362
OpenAlexW4281686111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.